The present invention relates to the preservation of collagenous connective tissue so as to achieve the structural integrality of the collagen fibers, rendering the tissue suitable for use in implants without causing immune and/or inflammatory rejection, comprising the steps of trimming the collagenous connective tissue in a buffer solution, washing the connective tissue with the buffer solution, stabilizing the tissue in an ethanol solution, treating the tissue with polyethylene glycol solution and hydrogen peroxide, washing and storing the tissue in ethanol, sterilizing the tissue with an ethanol and hydrogen peroxide solution and storing the tissue for transport in ethanol and indomethacin solution. The preferred use of the present invention is in surgical interventions for correcting various anomalies of the human body, where the graft is particularly required.

The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.

The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ.

The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.

Systems and methods are provided herein for monitoring electrical activity in ex vivo, resting donor organs. Systems and methods provided herein also include providing electrical stimulation to the donor tissue to maintain or increase viability during storage or transport. Donor organs can include ex vivo, resting hearts. Electrical activity can be used to determine donor organ viability, especially in instances where visual evaluation of a beating heart is not possible. The same electrodes or other sensing devices used to measure electrical activity can be used to apply a voltage/current to the tissue as well in order to maintain viability of the organ. In some embodiments, stimulation or depression may be provided in response to the measured electrical activity.

Systems and methods are provided herein for monitoring electrical activity in ex vivo, resting donor organs. Systems and methods provided herein also include providing electrical stimulation to the donor tissue to maintain or increase viability during storage or transport. Donor organs can include ex vivo, resting hearts. Electrical activity can be used to determine donor organ viability, especially in instances where visual evaluation of a beating heart is not possible. The same electrodes or other sensing devices used to measure electrical activity can be used to apply a voltage/current to the tissue as well in order to maintain viability of the organ. In some embodiments, stimulation or depression may be provided in response to the measured electrical activity.

A portable, ex vivo perfusion system for preserving detached biological tissue includes a receptacle for housing the tissue in a normothermic environment, a perfusion core to pump perfusate through the tissue via at least one conduit, at least one detection device to measure parameters during perfusion, and at least one parameter control device to maintain the parameter in a predetermined threshold. The system also include a controller with instructions to receive the measured parameters, compare the parameters to predetermined thresholds, and when the parameters are outside the thresholds change an output of the at least one parameter control device to get the parameters within the threshold and alert a user that parameters were outside the thresholds.

A portable, ex vivo perfusion system for preserving detached biological tissue includes a receptacle for housing the tissue in a normothermic environment, a perfusion core to pump perfusate through the tissue via at least one conduit, at least one detection device to measure parameters during perfusion, and at least one parameter control device to maintain the parameter in a predetermined threshold. The system also include a controller with instructions to receive the measured parameters, compare the parameters to predetermined thresholds, and when the parameters are outside the thresholds change an output of the at least one parameter control device to get the parameters within the threshold and alert a user that parameters were outside the thresholds.

A normothermic machine perfusion method for a pancreas is provided. First, a perfusate contained in a venous reservoir may be oxygenated such that a ratio of oxygen to carbon dioxide in the oxygenated perfusate is approximately 90%/10%. A first portion of the oxygenated perfusate may be pumped from the venous reservoir, through a dialysis filter, and back to the venous reservoir. A dialysate comprising a salt and glucose may be infused into the first portion of the oxygenated perfusate as the first portion is pumped through the dialysis filter. A concentration of glucose in the dialysate may be less than 8 mmol/L. A second portion of the oxygenated perfusate may be pumped through an arterial filter and through a pancreas graft. Venous outflow from the pancreas graft may then be pumped to the venous reservoir.